Physicians’, Nurses’ and Pharmacists’ Perceptions of Determinants to Deprescribing in Nursing Homes Considering Three Levels of Action: A Qualitative Study
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Individual Level Determinants: Clinical Uncertainty and Psychosocial Aspects
3.1.1. Numerous Medications Needed for Elderly Polymorbid Residents, Request for Specific Guidelines and Importance of Identifying Therapeutic Projects
“[…] these are polypathologies. If you have kidney failure, heart failure, plus Parkinson’s disease and diabetes, it will be very, very difficult to solve this with two or three medications.”(Phy6M: the gender of the participant is indicated after each quote (M for male and F for female) to inform about gender representation.)
“[…] in the end if you look at the guidelines in each medical domain, our patient will get ten medications, because in fact he has diabetes, he has hypertension: he has polymorbidity.”(Phy4F)
“Where do I start […] I’m trying to get out of the woods and it is the old branch, this one, I can cut it off for sure, it is useless.”(Pha10M)
“What is the project? Going back home? To reenergise them? Or is it a palliative project and in this case we will concentrate on analgesic medication?”(N2F)
3.1.2. Fear of Destabilisation and Physicians’ Responsibility
“They had trouble with people who had haemorrhages […] and who had to go back to the hospital. […] So they reintroduced them.”(Pha11M)
“If a balance has been found, we’re not going to start taking something away and then struggle to find a new balance.”(N8F)
“I also try to avoid a breakfast made of medication […] rather, what matters is that the patient has his breakfast and is not nauseated and is compliant with the indispensable medications.”(Phy1F)
“It makes us think quickly, to not prescribe too much, because one of the pills may not go down. So we need to choose the most important one.”(N2F)
3.1.3. Reluctance to Change to be due to Resident’s Age/Generation and Fears of Interruption of Care
“It’s not easy for them to reconsider this. It’s not when they are 90 years old that they will reconsider things.”(Pha4M)
“The generation that is currently residing in homes is a generation used to treating each illness with a pill. We have a different level of awareness.”(Pha5F)
“Some are hooked […] it may be because it is linked to the need to mourn their loss […] [Medication] represents the hope to be cured.”(N8F)
“For some residents, taking away some of their medication means we don’t really want to treat them, […] that death is near.”(Pha5F)
“Some families play a significant role. The fact that they may have heard that the pink pill was removed is problematical to them.”(Pha3M)
“In psychogeriatrics, they get worried that their loved one is not able to defend himself, if we are in a context where the medication is not appropriate because he cannot say anything or understand what is at stake, they feel this responsibility to defend him and know on his behalf what medication he takes. So it is even more important to talk to caretakers when the patient has dementia.”(Phy4F)
“The one that helps them sleep, they don’t forget (…) it’s also their purpose in life, to go to the toilet every day.”(N7F)
“Everything that directly impacts their quality of life will be very difficult to touch.”(Phy6M)
3.1.4. Residents’ Self-Determination and Importance of Communication with Residents and Relatives
“From a certain age, you obviously will have patients who will say, ‘I’m eighty years old, you’re not going to bother me about my sleeping pill, it’s the only thing that I have left, let me at least sleep well’ (…) it’s somewhat similar to the team who wants the patient to quit smoking when he’s 85 years old. In this case we are somehow thinking about end-of-life comfort, so to speak, I think we shouldn’t deprescribe just for the sake of it: ‘benzodiazepines are not good for you’, personally I feel it’s moralising.”(Pha10M)
“It may simply be a lack of communication. Because if we are patients, every day we receive a treatment and one morning, some things are missing because some people have decided for us, no one has explained anything to you, we don’t know why, this may be perceived as (...) pointless. One needs to understand this type of reaction. But if it is explained to the patient, it becomes obvious.”(Pha6F)
3.1.5. Finding the Right Timing, Rhythm and Conceiving Deprescribing as a Progressive and Reversible Process
“You have to get to know the patients and also their families and only then you declutter, you negotiate with the family to remove the medication that seems unnecessary.”(N2F)
“I have in mind a patient who is ultra-polymedicated. […] As I got to see her psyche, and the fact that she was addicted to her medication, I told her […] we would have to reduce, but I gave myself […] one year for it.”(Phy1F)
“I take it off but leave it in reserve. In one month, if we haven’t used it, we stop permanently. Reserves are a good tool to deprescribe, because it leaves some leniencies so that if things don’t go well, we can go back. It often works, and nurses know that they have tools in case it doesn’t work out. (…) It’s more there to reassure.”(Phy4F)
3.2. Institutional Determinants: Time Spent with Residents in NHs and Need for Interprofessional Collaboration
3.2.1. Lack of Time with NH Residents
“We are not the ones interacting with residents; it is something that is totally beyond us. We are fine with explaining to the physician and the nurse, that we can do, but the resident’s individual problems are totally beyond our sphere of influence.”(Pha5F)
“If I face resistance from a patient, when we know that from a medical standpoint, a medication doesn’t make much sense anymore, it’s often a question of time. Do I have time to talk for 30 min with them or do I postpone to the following month.”(Phy6M)
“Neuroleptics […] are sometimes there to compensate the staff shortage.”(Pha1F)
“I can imagine that if someone is slightly agitated one night, we may be tempted to give him what is in stock, may it be psychotropic or neuroleptic drugs, while all is needed is a glass of milk or a yogurt.”(Phy1F)
3.2.2. Autonomous Nurses Trained to Reduce Prescriptions and Favour non-Medicine Alternatives
“I have a question, I get an answer; I’m fine with phone prescriptions. In any case, for us, with our attending physician, it is also a matter of trust.”(N7F)
“Personally, I find that rather nonsensical. Even though we have our own areas of expertise and we can describe the situation very well, it still seems to me that a prescription shouldn’t be done over the phone.”(N1F)
“It’s difficult for them to understand that they are the ones who decide when they should give it (…). That they can decide with the patient when it is necessary and when it isn’t. (…) Reserve medications remain in reserve! When I need it, I take it, when I no longer need it, I don’t take it anymore.”(Phy3M)
“If I have nurses who are slightly more confident, who will ask less of physicians, consequently I will have also fewer prescriptions coming back, and in the end we will use the non-pharmaceutical nursing set of skills.”(N2F)
3.2.3. Referral to Specialists and Respect of Other Physicians’ Autonomy
“The problem is that it is the Word of God. When the psychiatrist speaks, (…) he is someone who is at the leading edge of knowledge in this particular field and (…) obviously the general practitioner (…) will not question his prescription.”(Pha5F)
“It’s really kind of taboo to go and say to a colleague, ‘don’t you think there are too many different psychotropic drugs, maybe you could stop one’. We don’t dare do that. It’s his patient; he’s the one who decides, and I don’t criticise that. […] Once I replaced him while he was on vacation and [a resident] is unwell and has four different types of medication, then I say (…) in the patient’s file: ‘The patient fell, he was confused, I stopped two psychotropic drugs’. I let my colleague know indirectly.”(Phy2F)
3.2.4. Interprofessional Communication Enabled by Integrated Pharmacist Services
“They are real discussions and we can see that they lead to good results. I can see real changes, it’s really good, it really improves medication practices.”(N4F)
“We created quality circles, there has been a drastic reduction of prescription or dosage and I think that had we not come and discussed it with the physicians, the curve would have remained low. We played a very important role there; we weren’t just initiators.”(Pha1F)
3.3. Healthcare System Determinants: Funding Time for Deprescribing and Need for Consistency within the Care Team
3.3.1. Lack of Funding for Comprehensive Treatment Reviews
“In a NH context, the whole polypharmacy thought process is performed when the patient is not there. Insurance companies don’t understand that you spend more time in the absence than in the presence of the patient. We’re up against a brick wall right now. At the same time, we can’t do a good job if we don’t know the diagnosis and if we don’t think about it carefully and if we don’t pick up the phone and call the pharmacists… the question is how this time can be paid.”(Phy1F)
3.3.2. Remuneration of the Pharmacist Based on Medication Delivery versus Pharmaceutical Services
“If there really is a treatment that ought to be given, to my mind, it has to be given whether it is expensive or not. We have to be careful that there aren’t any treatment restrictions.”(Pha2F)
“There is kind of trend of saying, ‘they are in a NH, they no longer need that’.”(Phy1F)
3.3.3. Multiplicity of Health Professionals versus Referents
“We have to work with 10 different physicians who don’t have a common philosophy. Not all physicians will have the same attitude. They all come on their own time, (…) once they have seen all the patients, at six in the evening, and we are pretty busy at that time.”(N9F)
4. Discussion
4.1. Individual Level: Working on Pedagogy while Respecting Complex Patient-Centred Care
4.2. Institutional Level: Finding Time and Improving Interprofessional Collaboration
4.3. Healthcare System: Coherent and Stable Healthcare Teams Paid for the Work Related to Deprescribing
4.4. Limitations and Perspectives
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
Ethics Approval and Consent to Participate
Availability of Data and Material
Abbreviations
F | female |
IPS | integrated pharmacist services |
M | male |
N | nurses |
NH | nursing home |
Pha | pharmacists |
Phy | physicians |
PIM | potentially inappropriate medication |
PPI | proton-pump inhibitor |
References
- Onder, G.; Liperoti, R.; Fialova, D.; Topinkova, E.; Tosato, M.; Danese, P.; Gallo, P.F.; Carpenter, I.; Finne-Soveri, H.; Gindin, J.; et al. Polypharmacy in nursing home in Europe: Results from the SHELTER study. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67, 698–704. [Google Scholar] [CrossRef] [Green Version]
- Schneider, R.; Reinau, D.; Schur, N.; Blozik, E.; Fruh, M.; Signorell, A.; Meier, C.R.; Schwenkglenks, M. Drug prescription patterns, polypharmacy and potentially inappropriate medication in Swiss nursing homes: A descriptive analysis based on claims data. Swiss Med. Wkly. 2019, 149, w20126. [Google Scholar] [CrossRef]
- Martin-Perez, M.; Ruigomez, A.; Pastor-Barriuso, R.; Garcia Lopez, F.J.; Villaverde-Hueso, A.; Damian, J. Number of Medications and Mortality Among Residents in Nursing Homes. J. Am. Med. Dir. Assoc. 2019, 20, 643–645. [Google Scholar] [CrossRef]
- Morin, L.; Laroche, M.-L.; Texier, G.; Johnell, K. Prevalence of Potentially Inappropriate Medication Use in Older Adults Living in Nursing Homes: A Systematic Review. J. Am. Med. Dir. Assoc. 2016, 17, 862.e1–862.e9. [Google Scholar] [CrossRef] [Green Version]
- Nyborg, G.; Brekke, M.; Straand, J.; Gjelstad, S.; Romøren, M. Potentially inappropriate medication use in nursing homes: An observational study using the NORGEP-NH criteria. BMC Geriatr. 2017, 17, 220. [Google Scholar] [CrossRef]
- Perri, M., 3rd; Menon, A.M.; Deshpande, A.D.; Shinde, S.B.; Jiang, R.; Cooper, J.W.; Cook, C.L.; Griffin, S.C.; Lorys, R.A. Adverse outcomes associated with inappropriate drug use in nursing homes. Ann. Pharmacother. 2005, 39, 405–411. [Google Scholar] [CrossRef]
- Gnjidic, D.; Hilmer, S.N.; Blyth, F.M.; Naganathan, V.; Waite, L.; Seibel, M.J.; McLachlan, A.J.; Cumming, R.G.; Handelsman, D.J.; Le Couteur, D.G. Polypharmacy cutoff and outcomes: Five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J. Clin. Epidemiol. 2012, 65, 989–995. [Google Scholar] [CrossRef]
- Turner, J.P.; Jamsen, K.M.; Shakib, S.; Singhal, N.; Prowse, R.; Bell, J.S. Polypharmacy cut-points in older people with cancer: How many medications are too many? Support. Care Cancer 2016, 24, 1831–1840. [Google Scholar] [CrossRef]
- Lau, D.T.; Kasper, J.D.; Potter, D.E.; Lyles, A.; Bennett, R.G. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch. Intern. Med. 2005, 165, 68–74. [Google Scholar] [CrossRef]
- Reeve, E.; Gnjidic, D.; Long, J.; Hilmer, S. A systematic review of the emerging definition of ‘deprescribing’ with network analysis: Implications for future research and clinical practice. Br. J. Clin. Pharmacol. 2015, 80, 1254–1268. [Google Scholar] [CrossRef] [Green Version]
- Wouters, H.; Scheper, J.; Koning, H.; Brouwer, C.; Twisk, J.W.; van der Meer, H.; Boersma, F.; Zuidema, S.U.; Taxis, K. Discontinuing Inappropriate Medication Use in Nursing Home Residents: A Cluster Randomized Controlled Trial. Ann. Intern. Med. 2017, 167, 609–617. [Google Scholar] [CrossRef]
- Page, A.T.; Clifford, R.M.; Potter, K.; Schwartz, D.; Etherton-Beer, C.D. The feasibility and the effect of deprescribing in older adults on mortality and health: A systematic review. Br. J. Clin. Pharmacol. 2016, 82, 583–623. [Google Scholar] [CrossRef]
- Reeve, E.; Thompson, W.; Farrell, B. Deprescribing: A narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. Eur. J. Intern. Med. 2017, 38, 3–11. [Google Scholar] [CrossRef] [Green Version]
- Palagyi, A.; Keay, L.; Harper, J.; Potter, J.; Lindley, R.I. Barricades and brickwalls—A qualitative study exploring perceptions of medication use and deprescribing in long-term care. BMC Geriatr. 2016, 16, 15. [Google Scholar] [CrossRef] [Green Version]
- Craig, P.; Dieppe, P.; Macintyre, S.; Michie, S.; Nazareth, I.; Petticrew, M. Developing and evaluating complex interventions: The new Medical Research Council guidance. Br. Med. J. 2008, 337, a1655. [Google Scholar] [CrossRef] [Green Version]
- Smart Health Care National Research Programme. Project 06 Optimising the Medication of Elderly Persons Living in Nursing Homes. Available online: http://www.nfp74.ch/en/projets/soins-stationnaires/projet-bugnon (accessed on 3 February 2020).
- Pluss-Suard, C.; Niquille, A.; Hequet, D.; Krahenbuhl, S.; Pichon, R.; Zanetti, G.; Bugnon, O.; Petignat, C. Decrease in Antibacterial Use and Facility-Level Variability After the Introduction of Guidelines and Implementation of Physician-Pharmacist-Nurse Quality Circles in Swiss Long-term Care Facilities. J. Am. Med. Dir. Assoc. 2020, 21, 78–83. [Google Scholar] [CrossRef] [Green Version]
- Locca, J.F.; Ruggli, M.; Buchmann, M.; Huguenin, J.; Bugnon, O. Development of pharmaceutical care services in nursing homes: Practice and research in a Swiss canton. Pharm. World Sci. 2009, 31, 165–173. [Google Scholar] [CrossRef]
- Rapport, F.; Clay-Williams, R.; Churruca, K.; Shih, P.; Hogden, A.; Braithwaite, J. The struggle of translating science into action: Foundational concepts of implementation science. J. Eval. Clin. Pract. 2018, 24, 117–126. [Google Scholar] [CrossRef] [Green Version]
- Niquille, A.; Ruggli, M.; Buchmann, M.; Jordan, D.; Bugnon, O. The nine-year sustained cost-containment impact of swiss pilot physicians-pharmacists quality circles. Ann. Pharmacother. 2010, 44, 650–657. [Google Scholar] [CrossRef]
- Guest, G.; Namey, E.; Taylor, J.; Eley, N.; McKenna, K. Comparing focus groups and individual interviews: Findings from a randomized study. Int. J. Soc. Res. Methodol. 2017, 20, 693–708. [Google Scholar] [CrossRef]
- Sandelowski, M. What’s in a name? Qualitative description revisited. Res. Nurs. Health 2010, 33, 77–84. [Google Scholar] [CrossRef] [PubMed]
- Tong, A.; Sainsbury, P.; Craig, J. Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups. Int. J. Qual. Health Care 2007, 19, 349–357. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Luymes, C.H.; van der Kleij, R.M.; Poortvliet, R.K.; de Ruijter, W.; Reis, R.; Numans, M.E. Deprescribing Potentially Inappropriate Preventive Cardiovascular Medication: Barriers and Enablers for Patients and General Practitioners. Ann. Pharmacother. 2016, 50, 446–454. [Google Scholar] [CrossRef]
- Reeve, E.; Wolff, J.L.; Skehan, M.; Bayliss, E.A.; Hilmer, S.N.; Boyd, C.M. Assessment of Attitudes Toward Deprescribing in Older Medicare Beneficiaries in the United States. JAMA Intern. Med. 2018, 178, 1673–1680. [Google Scholar] [CrossRef] [Green Version]
- Hurard, L.L.; Cateau, D.; Bugnon, O.; Niquille, A.; Foley, R.-A. Points de vue d’usagers sur la déprescription de médicaments en maison de retraite. Gerontol. Soc. 2020, 42, 171–187. [Google Scholar]
- Kalogianis, M.J.; Wimmer, B.C.; Turner, J.P.; Tan, E.C.; Emery, T.; Robson, L.; Reeve, E.; Hilmer, S.N.; Bell, J.S. Are residents of aged care facilities willing to have their medications deprescribed? Res. Soc. Adm. Pharm. 2016, 12, 784–788. [Google Scholar] [CrossRef]
- Kua, C.H.; Mak, V.S.L.; Huey Lee, S.W. Health Outcomes of Deprescribing Interventions Among Older Residents in Nursing Homes: A Systematic Review and Meta-analysis. J. Am. Med. Dir. Assoc. 2018, 20, 362–372. [Google Scholar] [CrossRef]
- Jansen, J.; Naganathan, V.; Carter, S.M.; McLachlan, A.J.; Nickel, B.; Irwig, L.; Bonner, C.; Doust, J.; Colvin, J.; Heaney, A.; et al. Too much medicine in older people? Deprescribing through shared decision making. Br. Med. J. 2016, 353, i2893. [Google Scholar] [CrossRef] [Green Version]
- Canadian Deprescribing Network, deprescribing.org. Available online: www.deprescribing.org (accessed on 24 January 2019).
- Goffman, E. Asylums: Essays on the Social Situation of Mental Patients and Other Inmates; AldineTransaction: London, UK, 1968; p. 336. [Google Scholar]
- Turner, J.P.; Edwards, S.; Stanners, M.; Shakib, S.; Bell, J.S. What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals. BMJ Open 2016, 6, e009781. [Google Scholar] [CrossRef] [Green Version]
- Baqir, W.; Hughes, J.; Jones, T.; Barrett, S.; Desai, N.; Copeland, R.; Campbell, D.; Laverty, A. Impact of medication review, within a shared decision-making framework, on deprescribing in people living in care homes. Eur. J. Hosp. Pharm. 2016, 24, 30–33. [Google Scholar] [CrossRef] [Green Version]
- Abbott, A. The System of Professions: An Essay on the Division of Expert Labor; University of Chicago Press: Chicago, IL, USA, 1988; pp. xvi, 435. [Google Scholar]
- Lundby, C.; Graabæk, T.; Ryg, J.; Søndergaard, J.; Pottegård, A.; Nielsen, D.S. Health care professionals’ attitudes towards deprescribing in older patients with limited life expectancy: A systematic review. Br. J. Clin. Pharmacol. 2019, 85, 868–892. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Professional Status | Sex | Hierarchy Level | Work Location (FR/VD) |
---|---|---|---|
Pharmacists (n = 11) | 5 men 6 women | 4 owners 7 employees including 1 manager | Canton FR = 5 Canton VD = 6 |
Nurses (n = 10) | 3 men 7 women | 3 head nurses 7 standard nurses | Canton FR = 6 Canton VD = 4 |
Physicians (n = 6) | 3 men 3 women | 4 head physicians 2 general practitioners | Canton FR = 2 Canton VD = 4 |
Nurses | Pharmacists | Physicians | ||
---|---|---|---|---|
1. Individual determinants | Clinical uncertainty facing complex NH residents | |||
Numerous medications needed for high age polymorbidity | X | |||
Guidelines for elderly polymorbid patients vs. by pathology | X | X | ||
Adaptation of the medication to the patient’s project | X | |||
Fear of destabilisation and physician’s responsibility | X | |||
Concern for adherence and elderly’s difficulty in swallowing | X | X | ||
Psycho-social aspects | ||||
Reluctance to change due to residents’ age/generation | X | X | X | |
Deprescribing seen as interruption of care | X | X | X | |
NH residents very attached to their medicines | X | X | ||
Residents’ self-determination | X | |||
Importance of communicating with residents and relatives | X | |||
Finding the right timing and rhythm for deprescribing | X | X | ||
Deprescribing as a progressive and reversible process | X | |||
2. Institutional determinants | Time spent with residents | |||
Lack of time with NHs residents | X | X | ||
Autonomous nurses trained to reduce prescriptions and favour non-medicine alternatives | X | X | ||
Interprofessional collaborations | ||||
Deference to specialists and respect of other physicians’ autonomy | X | X | ||
Interprofessional communication enabled by integrated pharmacist services | X | X | ||
3. Healthcare system determinants | Funding time for deprescribing | |||
Lack of funding for comprehensive treatment reviews | X | X | ||
Remuneration of the pharmacist based on medication dispensation versus pharmaceutical services | X | |||
(In)consistency within the care team | ||||
Multiplicity of professional caregivers versus referents | X |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Foley, R.-A.; Hurard, L.L.; Cateau, D.; Koutaissoff, D.; Bugnon, O.; Niquille, A. Physicians’, Nurses’ and Pharmacists’ Perceptions of Determinants to Deprescribing in Nursing Homes Considering Three Levels of Action: A Qualitative Study. Pharmacy 2020, 8, 17. https://doi.org/10.3390/pharmacy8010017
Foley R-A, Hurard LL, Cateau D, Koutaissoff D, Bugnon O, Niquille A. Physicians’, Nurses’ and Pharmacists’ Perceptions of Determinants to Deprescribing in Nursing Homes Considering Three Levels of Action: A Qualitative Study. Pharmacy. 2020; 8(1):17. https://doi.org/10.3390/pharmacy8010017
Chicago/Turabian StyleFoley, Rose-Anna, Lucie Lechevalier Hurard, Damien Cateau, Daria Koutaissoff, Olivier Bugnon, and Anne Niquille. 2020. "Physicians’, Nurses’ and Pharmacists’ Perceptions of Determinants to Deprescribing in Nursing Homes Considering Three Levels of Action: A Qualitative Study" Pharmacy 8, no. 1: 17. https://doi.org/10.3390/pharmacy8010017
APA StyleFoley, R. -A., Hurard, L. L., Cateau, D., Koutaissoff, D., Bugnon, O., & Niquille, A. (2020). Physicians’, Nurses’ and Pharmacists’ Perceptions of Determinants to Deprescribing in Nursing Homes Considering Three Levels of Action: A Qualitative Study. Pharmacy, 8(1), 17. https://doi.org/10.3390/pharmacy8010017